Table 2 Characteristics of registered COPD population in January 2022, grouped by their level of participation in the de-implementation program designed to reduce inappropriate use of ICS in COPD patients.
Program participants | Passive exposure to the program | ||
|---|---|---|---|
Full participation of practice (group A) (n = 608 patients) | Incomplete participation of practice (group B) (n = 744 patients) | (group C) (n = 2804 patients) | |
ICS use | |||
303 (49.8) | 393 (52.8) | 1433 (51.1) | |
Sex | |||
males | 296 (48.7) | 412 (55.4) | 1503 (53.6) |
Age | |||
<70 years | 302 (49.7) | 352 (47.3) | 1308 (46.6) |
70–80 years | 206 (33.9) | 260 (34.9) | 974 (34.7) |
>80 years | 100 (16.4) | 132 (17.7) | 522 (18.6) |
Smoking status | |||
Smoker | 218 (39.4) | 218 (32.4) | 898 (35.9) |
Ex-smoker | 291 (52.5) | 392 (58.2) | 1354 (54.2) |
never | 45 (8.1) | 63 (9.4) | 248 (10.0) |
unknown | 54 | 71 | 304 |
FEV1%predicted | |||
≥80% | 184 (36.3) | 207 (31.8) | 885 (36.8) |
≥50 - <80% | 283 (55.8) | 374 (57.5) | 1320 (54.9) |
≥30 - <50% | 33 (6.5) | 65 (10.0) | 200 (7.6) |
<30% | 7 (1.4) | 5 (0.7) | 13 (0.4) |
unknown | 101 | 93 | 386 |
CCQ-score | |||
≤1 | 310 (63.1) | 365 (56.2) | 1268 (58.0) |
>1 - ≤2 | 133 (27.1) | 186 (28.7) | 637 (29.2) |
>2 | 48 (9.8) | 98 (15.1) | 280 (12.8) |
unknown | 117 | 95 | 619 |
MRC-score | |||
0 | 89 (17.0) | 100 (15.9) | 393 (17.4) |
1 | 221 (42.2) | 246 (39.0) | 930 (41.1) |
2 | 144 (27.5) | 187 (29.7) | 618 (27.3) |
3–5 | 70 (13.4) | 97 (15.4) | 323 (14.3) |
unknown | 84 | 114 | 540 |
Courses of Prednisolone | |||
none | 499 (82.1) | 621 (83.5) | 2267 (80.8) |
1 | 56 (9.2) | 54 (7.3) | 256 (9.1) |
≥2 | 53 (8.7) | 69 (9.3) | 281 (10.0) |
